NewAmsterdam Pharma Company N.V.
NASDAQ:NAMSBiotechnology
+$0.12 today
- Market cap
- $2.37B
- Beta
- 0.08
- P/E (TTM)
- -17.2
- EPS (TTM)
- -$1.76
Volume 1.80M
Average 1.21M
NAMS Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
NewAmsterdam Pharma Company N.V.NASDAQ: NAMS
Operating Margin · Q2 FY2026 · quarter ended Jun 2026
Operating margin narrows to -1752.6%
Operating margin was -1752.6% in Q2 FY2026, down 1566.5 pp from a year earlier. On a trailing-twelve-month basis it was -3432.2%, down 3162.2 pp year over year. Over 3 fiscal years it narrowed by 999.4 pp.
Context
- Operating margin widened in 1 of the last 3 fiscal years.
What to watch
Whether operating margin reaches the consensus estimate from 10 analysts of -458.8% for the fiscal year ending Dec 2026, up from -1002.9% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -1752.6%+169.1 pp QoQ
- Last fiscal yearDec 2025
- -1002.9%-616.0 pp YoY
- LTMJun 2026
- -3432.2%-3162.2 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -1002.9%
- Year-over-year change
- -616.0pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -1002.9% | -616.0pp |
| FY2024 | 2024-12-31 | -386.9% | +911.6pp |
| FY2023 | 2023-12-31 | -1298.6% | -1295.1pp |
| FY2022 | 2022-12-31 | -3.5% | — |
| FY2021 | 2021-12-31 | — | — |
Operating Margin vs competitors
How NAMS compares with its peers on the latest reported figures
- NAMS's LTM Jun 2026 operating margin of -3432.2% is the 5th highest of the 6 companies compared; the peer median is -268.0%.
- Its year-over-year change of -3162.2 pp is the lowest of 5, against a peer median of +246.4 pp.
- Over three fiscal years its change of -999.4 pp compares with a peer median of +34.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | -25.1% | +35.0 pp | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | -76.2% | +273.0 pp | — |
| FY2025 | -268.0% | +219.7 pp | +34.6 pp | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -985.9% | +4653.4 pp | — |
| LTM Jun 2026 | -3432.2% | -3162.2 pp | -999.4 pp | |
| LTM Jun 2026 | -15058.2% | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding NAMS) | -268.0% | +246.4 pp | +34.6 pp | |
Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 102.69M | 14.09M | 45.56M | 22.5M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 59K |
| Gross Profit | 0 | 102.69M | 14.09M | 45.56M | 22.44M |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 99.7% |
| Research & Development | 28.97M | 86.74M | 159.42M | 151.41M | 141.83M |
| Selling, General & Admin | 5.68M | 19.51M | 37.63M | 70.45M | 106.3M |
| Operating Expenses | 34.98M | 106.25M | 197.06M | 221.85M | 248.13M |
| Depreciation & Amortization | 5K | 9K | 49K | 113K | 220K |
| EBITDA | (41.37M) | (22.34M) | (176.86M) | (241.49M) | (242.33M) |
| EBITDA Margin | — | -21.8% | -1255.2% | -530.0% | -1076.9% |
| Operating Income | (34.98M) | (3.56M) | (182.97M) | (176.29M) | (225.68M) |
| Operating Margin | — | -3.5% | -1298.6% | -386.9% | -1002.9% |
| Interest Income | 0 | 0 | 10.22M | 16.88M | 27.59M |
| Interest Expense | 411K | 287K | 6.8M | 0 | 0 |
| Other Income / Expenses | (6.81M) | (19.08M) | 6.06M | (65.31M) | 21.86M |
| Income Before Tax | (41.79M) | (22.63M) | (176.91M) | (241.6M) | (203.82M) |
| Pre-Tax Margin | — | -22.0% | -1255.6% | -530.3% | -905.7% |
| Income Tax Expense | 0 | 0 | 27K | (1K) | 0 |
| Net Income | (41.79M) | (22.63M) | (176.94M) | (241.6M) | (203.82M) |
| Net Margin | — | -22.0% | -1255.8% | -530.3% | -905.7% |
| EPS (Basic) | (3.34) | (1.19) | (2.15) | (2.56) | (1.75) |
| EPS (Diluted) | (3.34) | (1.19) | (2.15) | (2.56) | (1.75) |
| Weighted Avg Shares | 17.75M | 18.97M | 82.16M | 94.36M | 114.4M |
| Weighted Avg Shares (Diluted) | 17.75M | 18.97M | 82.16M | 94.36M | 114.4M |
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
Intrinsic Alpha fair value
Locked
Current Price
$19.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.